Showing results (251-260 of 324) with videos related to
Sort By:
Pageof 33
Cells|December 17, 2024
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to ImmunotherapyIslam Eljilany, Sam Coleman, Aik Choon Tan, et al.Journal of Translational Medicine|June 7, 2022
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021Paolo A Ascierto, Antonio Avallone, Nina Bhardwaj, et al.Journal for Immunotherapy of Cancer|April 19, 2019
Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisDaniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic CancerDonastas Sakellariou-Thompson, Marie-Andrée Forget, Caitlin Creasy, et al.Cancer|January 4, 2023
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohortWilliam N William, Jianjun Zhang, Xin Zhao, et al.Journal for Immunotherapy of Cancer|May 22, 2021
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanomaChantal Saberian, Rodabe N Amaria, Amer M Najjar, et al.Cancer Discovery|May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.Nature Communications|September 27, 2018
RNA editing derived epitopes function as cancer antigens to elicit immune responsesMinying Zhang, Jens Fritsche, Jason Roszik, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 15, 2018
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal MelanomaRené J Tavera, Marie-Andrée Forget, Young Uk Kim, et al.Melanoma Research|May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim, Sewa S Legha, Rene Gonzalez, et al.Pageof 33